179 related articles for article (PubMed ID: 19957160)
1. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.
Koïtka A; Cao Z; Koh P; Watson AM; Sourris KC; Loufrani L; Soro-Paavonen A; Walther T; Woollard KJ; Jandeleit-Dahm KA; Cooper ME; Allen TJ
Diabetologia; 2010 Mar; 53(3):584-92. PubMed ID: 19957160
[TBL] [Abstract][Full Text] [Related]
2. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Iwai M; Chen R; Li Z; Shiuchi T; Suzuki J; Ide A; Tsuda M; Okumura M; Min LJ; Mogi M; Horiuchi M
Circulation; 2005 Sep; 112(11):1636-43. PubMed ID: 16145000
[TBL] [Abstract][Full Text] [Related]
3. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lewis P; Stefanovic N; Pete J; Calkin AC; Giunti S; Thallas-Bonke V; Jandeleit-Dahm KA; Allen TJ; Kola I; Cooper ME; de Haan JB
Circulation; 2007 Apr; 115(16):2178-87. PubMed ID: 17420349
[TBL] [Abstract][Full Text] [Related]
4. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Candido R; Jandeleit-Dahm KA; Cao Z; Nesteroff SP; Burns WC; Twigg SM; Dilley RJ; Cooper ME; Allen TJ
Circulation; 2002 Jul; 106(2):246-53. PubMed ID: 12105166
[TBL] [Abstract][Full Text] [Related]
5. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Chow BS; Koulis C; Krishnaswamy P; Steckelings UM; Unger T; Cooper ME; Jandeleit-Dahm KA; Allen TJ
Diabetologia; 2016 Aug; 59(8):1778-90. PubMed ID: 27168137
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.
Cheng XW; Song H; Sasaki T; Hu L; Inoue A; Bando YK; Shi GP; Kuzuya M; Okumura K; Murohara T
Hypertension; 2011 May; 57(5):981-9. PubMed ID: 21464389
[TBL] [Abstract][Full Text] [Related]
8. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.
Watson AM; Li J; Samijono D; Bierhaus A; Thomas MC; Jandeleit-Dahm KA; Cooper ME
Atherosclerosis; 2014 Aug; 235(2):444-8. PubMed ID: 24945577
[TBL] [Abstract][Full Text] [Related]
9. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of betulinic acid on early atherosclerosis in diabetic apolipoprotein-E gene knockout mice.
Yoon JJ; Lee YJ; Han BH; Choi ES; Kho MC; Park JH; Ahn YM; Kim HY; Kang DG; Lee HS
Eur J Pharmacol; 2017 Feb; 796():224-232. PubMed ID: 27894808
[TBL] [Abstract][Full Text] [Related]
11. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
12. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse.
Thomas MC; Pickering RJ; Tsorotes D; Koitka A; Sheehy K; Bernardi S; Toffoli B; Nguyen-Huu TP; Head GA; Fu Y; Chin-Dusting J; Cooper ME; Tikellis C
Circ Res; 2010 Oct; 107(7):888-97. PubMed ID: 20671240
[TBL] [Abstract][Full Text] [Related]
13. The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.
Eto H; Miyata M; Shirasawa T; Akasaki Y; Hamada N; Nagaki A; Orihara K; Biro S; Tei C
Hypertens Res; 2008 Aug; 31(8):1631-42. PubMed ID: 18971539
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice.
Shemesh S; Kamari Y; Shaish A; Olteanu S; Kandel-Kfir M; Almog T; Grosskopf I; Apte RN; Harats D
Atherosclerosis; 2012 Jun; 222(2):329-36. PubMed ID: 22236482
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone does not attenuate diabetes-associated atherosclerosis.
Koh PJ; Koitka A; Cooper ME; Allen TJ
J Hypertens; 2009 Jul; 27(7):1431-8. PubMed ID: 19381106
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
18. Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice.
Menini S; Iacobini C; Ricci C; Blasetti Fantauzzi C; Pugliese G
Diabetologia; 2015 Apr; 58(4):845-53. PubMed ID: 25471794
[TBL] [Abstract][Full Text] [Related]
19. Elderly apolipoprotein E‑/‑ mice with advanced atherosclerotic lesions in the aorta do not develop Alzheimer's disease-like pathologies.
Shnerb Ganor R; Harats D; Schiby G; Rosenblatt K; Lubitz I; Shaish A; Salomon O
Mol Med Rep; 2018 Feb; 17(2):2488-2492. PubMed ID: 29207114
[TBL] [Abstract][Full Text] [Related]
20. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes.
Tikellis C; Pickering R; Tsorotes D; Du XJ; Kiriazis H; Nguyen-Huu TP; Head GA; Cooper ME; Thomas MC
Clin Sci (Lond); 2012 Oct; 123(8):519-29. PubMed ID: 22616805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
